Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
作者： Gini F. Fleming , Michael W. Sill , Kathleen M. Darcy , D. Scott McMeekin , J. Tate Thigpen
DOI: 10.1016/J.YGYNO.2009.09.025
关键词:
摘要: Purpose This study evaluated efficacy of single-agent trastuzumab against advanced or recurrent HER2-positive endometrial carcinoma (EC), and explored predictors for HER2 amplification.
gynecologiconcology-online.net
elsevier.com
sci-hub.se 参考文章(28)
Laura, M. Bender, Her2 cross talk and therapeutic resistance in breast cancer Frontiers in Bioscience. ,vol. Volume, pp. 3906- 3912 ,(2008) , 10.2741/2978
T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstråle, O.I. Olopade, G.F. Fleming, An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study Gynecologic Oncology. ,vol. 108, pp. 3- 9 ,(2008) , 10.1016/J.YGYNO.2007.09.007
E. Van Cutsem, Y.K. Kang, L. Shen, F. Lordick, A. Ohtsu, T. Satoh, J. Hill, M. Lehle, A. Feyereislova, Y.J. Bang, 7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial Ejc Supplements. ,vol. 7, pp. 7- ,(2009) , 10.1016/S1359-6349(09)72042-7
T. Timothy Chen, Tie-Hua Ng, Optimal flexible designs in phase II clinical trials. Statistics in Medicine. ,vol. 17, pp. 2301- 2312 ,(1998) , 10.1002/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X
Michael A. Bookman, Kathleen M. Darcy, Daniel Clarke-Pearson, Richard A. Boothby, Ira R. Horowitz, Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group Journal of Clinical Oncology. ,vol. 21, pp. 283- 290 ,(2003) , 10.1200/JCO.2003.10.104
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva, Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 269- 280 ,(2006) , 10.1038/NCPONC0509
G Peiró, D Mayr, P Hillemanns, U Löhrs, J Diebold, Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Modern Pathology. ,vol. 17, pp. 277- 287 ,(2004) , 10.1038/MODPATHOL.3800006
David L. Shattuck, Jamie K. Miller, Kermit L. Carraway, Colleen Sweeney, Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research. ,vol. 68, pp. 1471- 1477 ,(2008) , 10.1158/0008-5472.CAN-07-5962
S. Kang, S. S. Seo, H. J. Chang, C. W. Yoo, S. Y. Park, S. M. Dong, Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma International Journal of Gynecological Cancer. ,vol. 18, pp. 1339- 1343 ,(2008) , 10.1111/J.1525-1438.2007.01172.X
Alessandro D. Santin, Stefania Bellone, Sue Van Stedum, Wendy Bushen, Luis E. De Las Casas, Soheila Korourian, Erming Tian, Juan J. Roman, Alexander Burnett, Sergio Pecorelli, Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecologic Oncology. ,vol. 98, pp. 24- 30 ,(2005) , 10.1016/J.YGYNO.2005.03.041